RNA Based Therapeutics and Vaccines Market Outlook

According to FutureWise analysis the RNA Based Therapeutics and Vaccines Market in 2025 is US$ 1.27 billion, and is expected to reach US$ 1.96 billion by 2033 at a CAGR of 5.57%. The growth in mRNA technology is driven by increased investment, successful use in COVID-19 vaccines, and research in rare genetic disorders and cancer. RNA platforms' flexibility and adaptability position them as key players in personalized medicine and next-generation vaccine development.

RNA therapeutics represent an innovative category of medical interventions that focus on ribonucleic acid (RNA). This field includes various segments: messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers. Among these, mRNA-based therapy is particularly notable for its ability to stimulate protein synthesis within cells, making it especially valuable in vaccine development.

Antisense RNA works by pairing with coding mRNA, leading to the inactivation of the mRNA and halting its role in protein translation. Similarly, RNA interference (RNAi) systems utilize small interfering RNA (siRNA) and microRNA (miRNA) to inhibit mRNA translation and promote its degradation.

In contrast, RNA aptamers are short, single-stranded RNA molecules created through directed evolution. They can bind tightly to various biomolecular targets, influencing their in vivo functions. RNA is transcribed from a template DNA by RNA polymerase, with messenger RNA (mRNA) serving as the intermediary that links DNA expression to protein translation.

RNA has unique characteristics, such as its often single-stranded structure, the presence of a 2' hydroxyl (OH) group, and its ability to adopt diverse secondary and tertiary structures, all of which have sparked significant medical interest. The exploration of RNA's therapeutic potential presents unique challenges during drug discovery and the development of RNA-based treatments. This field began in the 1990s and has made remarkable progress, particularly in cancer therapy in the early 2010s. The global emergence of mRNA vaccines in 2020 and 2021 was a pivotal moment in response to the COVID-19 pandemic. The Pfizer-BioNTech COVID-19 vaccine became the first mRNA vaccine to receive regulatory approval, followed by the Moderna COVID-19 vaccine and other candidates.

FutureWise Market Research has published a report that provides an insightful analysis of RNA based Therapeutics and Vaccines Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=264&type=requestsample

RNA based Therapeutics and Vaccines Market Segmentation:

By Product Type

• RNA-based Therapeutics
  • sIRNA
  • miRNA
• RNA-based Vaccines
  • mRNA

By Indication Type

• Oncology
• Immunology
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Genetic Diseases
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in RNA based Therapeutics and Vaccines Market:

• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma Corp.
• Arrowhead Pharmaceuticals, Inc.
• BioNTech AG
• CureVac AG
• Dicerna Pharmaceuticals, Inc.
• Regulus Therapeutics, Inc.
• Marina Biotech, Inc.
• miRagen Therapeutics
• Moderna Therapeutics, Inc.
• Quark Pharmaceuticals, Inc.
• Santaris Pharma A/S (A Roche Company)
• Sylentis S.A.

Moderna

• mNEXSPIKE™—a next-generation mRNA COVID-19 vaccine—received FDA approval in May 2025 for adults aged 65 and older, as well as for high-risk individuals aged 12 to 64. This vaccine offers improved stability, allowing for storage in a refrigerator, and demonstrates superior efficacy compared to earlier versions. It is expected to be rolled out during the 2025–2026 respiratory season.
• Moderna's seasonal influenza vaccine (mRNA-1010) in Phase III has exceeded its enrollment targets, with interim efficacy results expected in summer 2025. Additionally, Moderna is progressing with its combined flu/COVID vaccine (mRNA-1083), which is currently in the regulatory submission phase, aiming for approval by 2026.

BioNTech

• In June 2025, the acquisition of CureVac for approximately $1.25 billion marks a consolidation in mRNA cancer immunotherapies as BioNTech enhances its global manufacturing capabilities and expands its pipeline depth.
• In 2023, the acquisition of InstaDeep enhanced its AI-driven drug discovery capabilities, leading to the development of platforms such as CARVac-loaded CAR-T cells targeting Claudin-6 and autogene cevumeran, an individualized cancer vaccine that shows a promising immune response in pancreatic cancer.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=264&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the RNA based Therapeutics and Vaccines Market By Product Type, By Indication Type and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/78283-RNA-Based-Therapeutics-and-Vaccines-Market-Outlook.html